Abstract
A chronic inflammatory response possibly mediated by Amyloid β (Aβ) is believed to be a major factor in the pathology of Alzheimer's disease (AD). Studies suggest that the mediators of the inflammatory response, which might contribute to brain damage, involve cytokines, such as IL-1β. IL-1β could play an important part in the development of pathologic conditions. There is also an endogenous interleukin-1 receptor antagonist (IL-1RA) in IL-1 family, which could prevent the actions of IL-1β by competing for receptor binding without inducing any signal transduction. Therefore, the balance of IL-1β vs IL-1RA is a critical parameter in determining not only whether excessive host inflammation will occur, but also the degree of subsequent host cell damage and associated toxicity. In our previous study, it has been determined that the anti-inflammatory action of Gossypium herbaceam L. extracts (GHE) was involved in its neuroprotection. However, the effects of GHE on IL-1β and IL-1RA have not been clearly defined in the experimental rat model of AD induced by Aβ. Therefore, the current study is performed to evaluate whether GHE could affect the disequilibrium of IL-1RA/IL-1β ratio in the hippocampus of rats after Aβ treatment. Subsequently, we further identify that GHE could efficaciously promote Akt and GSK3β phosphorylation, and thereby contribute to IL-1β release decrease as well as a concurrent increase in the level of IL-1RA through NF-κB and MAPK pathways. As a consequence, GHE is potentially beneficial to maintain the endogenous IL-1RA/ IL-1β balance in the hippocampus of rats and it might be a potential agent to ameliorate inflammatory process in AD.
Keywords: Alzheimer's disease, Amyloid β (Aβ), Gossypium herbaceam L., IL-1β; IL-1RA, JNK
Current Alzheimer Research
Title:Gossypium herbaceam L. Extracts Ameliorate Disequilibrium of IL- 1RA/IL-1β Ratio to Attenuate Inflammatory Process induced by Amyloid β in Rats
Volume: 9 Issue: 8
Author(s): Chao Ji, Cai Song, Haji Akber Aisa, Nan Yang, Yan-Yong Liu, Qing Li, Hai-Bo Zhu and Ping-Ping Zuo
Affiliation:
Keywords: Alzheimer's disease, Amyloid β (Aβ), Gossypium herbaceam L., IL-1β; IL-1RA, JNK
Abstract: A chronic inflammatory response possibly mediated by Amyloid β (Aβ) is believed to be a major factor in the pathology of Alzheimer's disease (AD). Studies suggest that the mediators of the inflammatory response, which might contribute to brain damage, involve cytokines, such as IL-1β. IL-1β could play an important part in the development of pathologic conditions. There is also an endogenous interleukin-1 receptor antagonist (IL-1RA) in IL-1 family, which could prevent the actions of IL-1β by competing for receptor binding without inducing any signal transduction. Therefore, the balance of IL-1β vs IL-1RA is a critical parameter in determining not only whether excessive host inflammation will occur, but also the degree of subsequent host cell damage and associated toxicity. In our previous study, it has been determined that the anti-inflammatory action of Gossypium herbaceam L. extracts (GHE) was involved in its neuroprotection. However, the effects of GHE on IL-1β and IL-1RA have not been clearly defined in the experimental rat model of AD induced by Aβ. Therefore, the current study is performed to evaluate whether GHE could affect the disequilibrium of IL-1RA/IL-1β ratio in the hippocampus of rats after Aβ treatment. Subsequently, we further identify that GHE could efficaciously promote Akt and GSK3β phosphorylation, and thereby contribute to IL-1β release decrease as well as a concurrent increase in the level of IL-1RA through NF-κB and MAPK pathways. As a consequence, GHE is potentially beneficial to maintain the endogenous IL-1RA/ IL-1β balance in the hippocampus of rats and it might be a potential agent to ameliorate inflammatory process in AD.
Export Options
About this article
Cite this article as:
Ji Chao, Song Cai, Akber Aisa Haji, Yang Nan, Liu Yan-Yong, Li Qing, Zhu Hai-Bo and Zuo Ping-Ping, Gossypium herbaceam L. Extracts Ameliorate Disequilibrium of IL- 1RA/IL-1β Ratio to Attenuate Inflammatory Process induced by Amyloid β in Rats, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251093
DOI https://dx.doi.org/10.2174/156720512803251093 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Recent Advances in the Design of Cathepsin S Inhibitors
Current Topics in Medicinal Chemistry Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Assessment of rhIL-11 by Validated SE-LC Method and its Correlation with RP-LC and CZE Methods
Current Pharmaceutical Analysis The Influence of Different Disease States on Rituximab Pharmacokinetics
Current Drug Metabolism Elastic Liposomes for Topical and Transdermal Drug Delivery
Current Drug Delivery Retinoid X Receptor Selective Agonists and their Synthetic Methods
Current Topics in Medicinal Chemistry The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry Prostacyclin Synthase Gene: Implication and Prevention of Cardiovascular Disease
Vascular Disease Prevention (Discontinued) A QSAR Study on Some Series of Anti-Hepatitis C Virus (HCV) Agents
Letters in Drug Design & Discovery Neutrophil Derived Microvesicles: Emerging Role of a Key Mediator to the Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of MHC II Gene Transcription by Nitric Oxide and Antioxidants
Current Pharmaceutical Design FOXP3: Required but Not Sufficient. The Role of GARP (LRRC32) as a Safeguard of the Regulatory Phenotype
Current Molecular Medicine Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1
Current Medicinal Chemistry The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus
Current Neurovascular Research Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists
Current Pharmaceutical Design